The BiTE construct has been engineered to exhibit dual binding affinity for EpCAM+ tumor cells and CD3+ T cells, leading to the formation of clusters and subsequent activation of CD4+ and CD8+ T cells alongside with cancer cells. The gene discussed is CD8A; the disease is neoplasm.